Evidence map›Paper›PMID 35170199›Full record

ArticleJournal of cellular and molecular medicine2022

Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR-34c-5p/LGR4/β-catenin axis activity.

Li-Hua Lyu, Chun-Yan Zhang, Wen-Jing Yang, An-Li Jin, Jie Zhu, Hao Wang, Te Liu, Bei-Li Wang, Jian-Wen Cheng, Xin-Rong Yang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Li-Hua LyuDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Chun-Yan ZhangDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Wen-Jing YangDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
An-Li JinDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Jie ZhuDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Hao WangDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Te LiuShanghai Geriatric Institute of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0003-3976-3489
Bei-Li WangDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Jian-Wen ChengDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xin-Rong YangDepartment of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Wei GuoDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-4406-1094
Sun Yat-sen University · CNMinistry of Education of the People's Republic of China · CNShanghai University of Traditional Chinese Medicine · CN

Funding

key medical and health projects of Xiamen YDZX20193502000002National Key R&D Program of China 2019YFC1315800National Key R&D Program of China 2019YFC1315802National Natural Science Foundation of China 81772551National Natural Science Foundation of China 81772578National Natural Science Foundation of China 81872355National Natural Science Foundation of China 81902139National Natural Science Foundation of China 81972000National Natural Science Foundation of China 82072715Shanghai Municipal Health Commission Collaborative Innovation Cluster Project 2019CXJQ02Shanghai Municipal Key Clinical Specialty, and specialized fund for the clinical researches of Zhongshan Hospital affiliated Fudan University 2018ZSLC05Shanghai "Rising Stars of Medical Talent" Youth Development Program (Outstanding Youth Medical Talents), the Projects from the Shanghai Science and Technology Commission 19441905000State Key Program of National Natural Science of China 81830102
6 · The paper itself

Abstract

Accumulating evidence suggests that circular RNAs (circRNAs) play essential roles in regulating cancer progression, but many circRNAs in hepatocellular carcinoma (HCC) remain unknown. Dysregulated circRNAs in HCC were identified through bioinformatics analysis of Gene Expression Omnibus data sets. Quantitative real-time PCR (qRT-PCR), Sanger sequencing, RNase R digestion and actinomycin D treatment were conducted to confirm the characterization of circRNAs. CCK-8, wound-healing and Transwell assays were performed to assess the functional roles of Hsa_circ_0003945 (Circ_0003945) in HCC cell lines. Subcellular fractionation and fluorescence in situ hybridization (FISH) were performed to locate Circ_0003945 in HCC cells. Dual-luciferase reporter assay was executed to verify the binding of Circ_0003945 to microRNAs (miRNAs) or the miRNAs to their target genes. In this study, we found that Circ_0003945 was upregulated in HCC tissue, and higher Circ_0003945 expression was positively correlated with tumour size and tumour stage. Furthermore, high plasma levels of circulating Circ_0003945 were confirmed in HCC patients compared with those in non-HCC groups. The functional experiments revealed that overexpression or knockdown of Circ_0003945 promoted or attenuated tumour growth and migration, respectively. Mechanistically, Circ_0003945 might exert as a miR-34c-5p sponge to upregulate the expression of leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4), activating the β-catenin pathway, and finally facilitating HCC progression. Additionally, a β-catenin activator could reverse the effect of Circ_0003945 knockdown. In conclusion, Circ_0003945 exerts a tumour-promoting role in HCC cells by regulating the miR-34c-5p/LGR4/β-catenin axis, which may be a potential target for HCC therapy.

Indexed as

beta CateninCarcinoma, HepatocellularLiver NeoplasmsMicroRNAsReceptors, G-Protein-CoupledCell Line, TumorCell ProliferationHumansIn Situ Hybridization, FluorescenceRNA, CircularSignal Transductionbeta CateninCTNNB1 protein, humanLGR4 protein, humanMicroRNAsMIRN34 microRNA, humanReceptors, G-Protein-CoupledRNA, CircularCirc_0003945hepatocellular carcinomaleucine-rich repeat-containing G protein-coupled receptor 4miR-34c-5ptumour progression

Identifiers

PMID35170199
PMCPMC8995453
OpenAlexW4212982234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.